Nitrogen dioxide increases the risk of disease progression in idiopathic pulmonary fibrosis
- PMID: 36123769
- DOI: 10.1111/resp.14373
Nitrogen dioxide increases the risk of disease progression in idiopathic pulmonary fibrosis
Abstract
Background and objective: Air pollution affects clinical course and prognosis of idiopathic pulmonary fibrosis (IPF). However, the effect of individual exposure to air pollutants on disease progression is unclear. We aimed to identify the effect of individual exposure to nitrogen dioxide (NO2 ) and particulate matter (aerodynamic diameter ≤ 10 μm [PM10 ]) on disease progression in patients with IPF.
Methods: The serial lung function data of 946 IPF patients (mean age: 65.4 years, male: 80.9%) were analysed. Individual-level long-term exposures to NO2 and PM10 at the residential addresses of patients were estimated using a national-scale exposure prediction model, constructed based on air quality regulatory monitoring data. Progression was defined as a relative decline (≥10%) in forced vital capacity. Individual- and area-level covariates were adjusted in the primary analysis model.
Results: Overall, 547 patients (57.8%) experienced progression during a median follow-up of 1.0 year (interquartile range: 0.4-2.6 years). In the primary model, a 10-ppb increase in NO2 concentration was associated with a 10.5% increase in the risk of progression (hazard ratio [HR] = 1.105; 95% CI = 1.000-1.219) in patients with IPF. There was also an increasing trend of progression in patients with IPF according to the second to fourth quartiles of NO2 (Q2 [HR = 1.299; 95% CI = 0.972-1.735], Q3 [1.409; 1.001-1.984], Q4 [1.598; 1.106-2.310]) compared to the first quartile. We found no association between PM10 and progression in IPF patients.
Conclusion: Our data suggest that increased individual exposure to NO2 can increase the risk of progression in patients with IPF.
Keywords: air pollutant; disease progression; idiopathic pulmonary fibrosis; lung function; prognosis.
© 2022 Asian Pacific Society of Respirology.
Comment in
-
"Safe air" to breathe: Time for action?Respirology. 2023 Mar;28(3):210-211. doi: 10.1111/resp.14469. Epub 2023 Feb 7. Respirology. 2023. PMID: 36750441 No abstract available.
References
REFERENCES
-
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
-
- Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2:566-72.
-
- King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164:1171-81.
-
- Lee SH, Yeo Y, Kim TH, Lee HL, Lee JH, Park YB, et al. Korean guidelines for Diagnosis and Management of Interstitial Lung Diseases. Part 2. Idiopathic pulmonary fibrosis. Tuberc Respir Dis. 2019;82:102-17.
-
- Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172:488-93.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
